Kura Oncology (KURA)
(Real Time Quote from BATS)
$20.99 USD
+0.36 (1.75%)
Updated May 6, 2024 12:40 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KURA 20.99 +0.36(1.75%)
Will KURA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for KURA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KURA
Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations
What Makes Kura Oncology (KURA) a New Buy Stock
KURA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kura Oncology (KURA) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Wall Street Analysts Believe Kura Oncology (KURA) Could Rally 111%: Here's is How to Trade
Is Kura Oncology (KURA) Stock Outpacing Its Medical Peers This Year?
Other News for KURA
Analysts Are Bullish on These Healthcare Stocks: Relay Therapeutics (RLAY), Kura Oncology (KURA)
Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Kura Oncology (KURA) and Amgen (AMGN)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scotiabank Keeps Their Hold Rating on Kura Oncology (KURA)